Back to Agenda
Real-World Evidence (RWE) in Drug Development – Creating the Right Environment for Enhanced Pre-Launch Evidence
Session Chair(s)
Pieter Stolk, PharmD, PhD
Project Manager, University Medical Centre Utrecht, Netherlands
Real-World Evidence (RWE) in Drug Development – Creating the Right Environment for Enhanced Pre-Launch Evidence
Speaker(s)
François Meyer, MD
Advisor to the President, International Affairs, French National Authority for Health (HAS), France
How Can Future Pre-Launch Studies Provide Information on the Relative Effectiveness of a New Medicine: Lessons from the Influence of ‘Real-World Data’ on the Reassessment of Pharmaceuticals
Iris Goetz, MD, MSc
Epidemiologist, Global Health Outcomes, Eli Lilly and Company, United Kingdom
What are the Operational/Feasiblity Challenges in Conducting RWE Studies – Pragmatic Trials, As an Example
Chris Chinn, MSc
Real World Evidence for Market Access, Sanofi, United Kingdom
Acceptability of RWE: A Key Factor for R&D Decision-Making Pre- vs Post- Launch
Have an account?